Gimenez, N., Martinez-Trillos, A., Montraveta, A., Lopez-Guerra, M., Rosich, L., Nadeu, F., . . . Villamor, N. (2019). Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia.
Citação norma ChicagoGimenez, N., et al. Mutations in the RAS-BRAF-MAPK-ERK Pathway Define a Specific Subgroup of Patients With Adverse Clinical Features and Provide New Therapeutic Options in Chronic Lymphocytic Leukemia. 2019.
Citação norma MLAGimenez, N., et al. Mutations in the RAS-BRAF-MAPK-ERK Pathway Define a Specific Subgroup of Patients With Adverse Clinical Features and Provide New Therapeutic Options in Chronic Lymphocytic Leukemia. 2019.